Rinehart J, LaForge J, Gochnour D, Neidhart J
Cancer Immunol Immunother. 1987;24(3):244-6. doi: 10.1007/BF00205637.
MVE-II, a low molecular weight fraction of pyran copolymer was utilized in a Phase II trial in patients with metastatic malignant melanoma. A total of 15 patients were investigated and no clinical responses or immunologic responses were observed. We concluded that MVE-II is not an active agent in malignant melanoma.
MVE-II,一种吡喃共聚物的低分子量组分,被用于转移性恶性黑色素瘤患者的II期试验。共对15名患者进行了研究,未观察到临床反应或免疫反应。我们得出结论,MVE-II在恶性黑色素瘤中不是一种活性药物。